134 related articles for article (PubMed ID: 10618689)
1. Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Novik Y; Ryan LM; Haller DG; Asbury R; Dutcher JP; Schutt A
Med Oncol; 1999 Dec; 16(4):261-6. PubMed ID: 10618689
[TBL] [Abstract][Full Text] [Related]
2. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Asbury RF; Cnaan A; Johnson L; Harris J; Zaentz SD; Haller DG
Am J Clin Oncol; 1994 Apr; 17(2):166-9. PubMed ID: 8141110
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of spirogermanium in patients with advanced colorectal carcinoma.
Ajani JA; Faintuch JS; McClure RK; Levin B; Boman BM; Krakoff IH
Invest New Drugs; 1986; 4(4):383-5. PubMed ID: 3583645
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
Ettinger DS; Finkelstein DM; Abeloff MD; Chang YC; Smith TJ; Oken MM; Ruckdeschel JC
Invest New Drugs; 1990 May; 8(2):183-5. PubMed ID: 2166720
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of spirogermanium in advanced large bowel cancer. An Eastern Cooperative Oncology Group study.
Pandya KJ; Kramar A; Asbury RF; Haller DG
Am J Clin Oncol; 1988 Aug; 11(4):496-8. PubMed ID: 3407630
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
Med Pediatr Oncol; 1989; 17(3):197-201. PubMed ID: 2546026
[TBL] [Abstract][Full Text] [Related]
9. Oral etoposide for patients with metastatic gastric adenocarcinoma.
Ajani JA; Mansfield PF; Dumas P
Cancer J Sci Am; 1999; 5(2):112-4. PubMed ID: 10198733
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of mitoxantrone in advanced gastric cancer.
Levi JA; Gill PG; Presgrave P
Invest New Drugs; 1990 Aug; 8(3):305-6. PubMed ID: 2272769
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer.
Içli F; Karaoguz H; Akbulut H; Dinçol D; Demirkazik A; Cay F
J Surg Oncol; 1997 Apr; 64(4):318-23. PubMed ID: 9142190
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.
Saiers JH; Blumenstein B; Slavik M; Costanzi JH; Crawford ED
Cancer Treat Rep; 1987 Dec; 71(12):1305-6. PubMed ID: 3690546
[No Abstract] [Full Text] [Related]
13. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.
Paciucci PA; Davis RB; Holland JF; Martelo O; Schiffer CA
Am J Clin Oncol; 1990 Dec; 13(6):516-9. PubMed ID: 2239806
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study.
Lad TE; Blough RR; Evrard M; Shevrin DP; Cobleigh MA; Johnson CM; Hange P
Invest New Drugs; 1989 Jul; 7(2-3):223-4. PubMed ID: 2551841
[TBL] [Abstract][Full Text] [Related]
15. Oral etoposide for patients with advanced adenocarcinoma of the pancreas.
Thomas E; Dumas P; Ajani JA
Invest New Drugs; 1998-1999; 16(4):333-5. PubMed ID: 10426667
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
[TBL] [Abstract][Full Text] [Related]
18. An early phase II study of etoposide (VP-16) in advanced gastric cancer.
Yamao T; Shimada Y; Ohtsu A; Hosokawa K; Shirao K; Kondo H; Fukuda H; Saito D; Yoshida S
Jpn J Clin Oncol; 1996 Feb; 26(1):36-41. PubMed ID: 8551665
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
[TBL] [Abstract][Full Text] [Related]
20. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thuss-Patience PC; Kretzschmar A; Bichev D; Deist T; Hinke A; Breithaupt K; Dogan Y; Gebauer B; Schumacher G; Reichardt P
Eur J Cancer; 2011 Oct; 47(15):2306-14. PubMed ID: 21742485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
